A handful of major diagnostics companies are flush with unprecedented gains from COVID-19 testing revenues. Hologic is using its COVID windfall to reshape its business in a post-pandemic world even as investors worry that the momentum is unsustainable.
Welcome to MyStrategist, the digital home for MedTech Strategist.
MedTech Strategist, the global medical device industry's most trusted resource, will help you stay ahead of the opportunities and obstacles that are impacting your corporate strategy. We invite you to explore our coverage. Think Strategically. Subscribe TodayBrowse Latest Issue
Trial MyStrategist.com and unlock 7-days of exclusive subscriber-only access to MedTech Strategist & Market PathwaysStart Trial
Many epilepsy patients cannot live the lives they want because of the unpredictability of seizures. The founders of Nile AI believe that doesn’t have to be the case. Spun-off from UCB, a leader in the development of epilepsy drugs, Nile AI is developing a systematic solution in a platform that unites all epilepsy stakeholders in the goal of rapidly getting each patient into the therapy that works best for them
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.Learn More
After a pause in fundraising caused by the pandemic, Endeavour Vision recently closed its latest fund and has already made eight investments.